Topic
BEAT platform
News
1 Jun 2026
Glenmark Pharma posts robust Q4; ISB 2001 AbbVie pact and Ryaltris momentum mark ‘defining year’
Glenmark Pharmaceuticals reported a strong performance for the March quarter and the full year ended March 31, 2026, with double‑digit…
News
21 May 2026
Ichnos Glenmark Innovation (IGI) advances solid‑tumor candidate ISB 2301 after completing pre‑clinical development
Glenmark Pharmaceuticals’ innovation arm, Ichnos Glenmark Innovation (IGI), has completed pre‑clinical development of ISB 2301, a next‑generation multispecific antibody for…